Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9221868 | 1.00 | EPHX1 (0.48) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL3389395 | 0.99 | EPHX1 (0.46) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL571421 | 0.93 | CTSK (0.47) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL9822629 | 0.87 | EPHX1 (0.44) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL9221873 | 0.86 | EPHX1 (0.46) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL7359182 | 0.85 | HDAC4 (0.42) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL7331006 | 0.85 | HDAC4 (0.42) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL10713649 | 0.85 | HDAC4 (0.42) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL15795844 | 0.84 | CTSK (0.40) | EPHX1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL7328387 | 0.84 | CTSK (0.43) | EPHX1HDAC4HDAC1HDAC6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268863-B2 | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110144152-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7947710-B2 | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2195314-B1 | DISUBSTITUTED ALKYL-8-AZABICYCLO [3.2.1.]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090062332-A1 | Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists | THERAVANCE, INC | 2009-03-05 | — | — | US | disclosed |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1448525-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1368314-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003042178-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002070479-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| EP-0349570-A1 | RENIN INHIBITORS CONTAINING A CYCLOPROPYL AMINO ACID AND/OR A CYCLOALKYL TRANSITION-STATE ANALOGUE | THE UPJOHN COMPANY (US) | 1990-01-10 | — | — | EP | disclosed |
| US-4882420-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1989-11-21 | — | — | US | disclosed |
| WO-1988007053-A1 | RENIN INHIBITORS CONTAINING A CYCLOPROPYL AMINO ACID AND/OR A CYCLOALKYL TRANSITION-STATE ANALOGUE | THE UPJOHN COMPANY (US) | 1988-09-22 | — | — | WO | disclosed |
| EP-0218688-A1 | DIHALO-STATINE SUBSTITUTED RENIN INHIBITORS. | UPJOHN CO (US) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986006379-A1 | DIHALO-STATINE SUBSTITUTED RENIN INHIBITORS | THE UPJOHN COMPANY (US) | 1986-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CX3CR1 | EPHX1 1231/4885HDAC4 2632/4885HDAC1 1052/4885 |
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | EPHX1 2047/4885HDAC4 917/4885HDAC1 791/4885 |
| US-20090062332-A1 | Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | EPHX1 2630/4885HDAC4 1478/4885HDAC1 488/4885 |
| US-20110144152-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | EPHX1 2630/4885HDAC4 1478/4885HDAC1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.